447 related articles for article (PubMed ID: 19662600)
1. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
2. [Immunogical surveillance and oncogenesis: role of proliferation signal inhibitors].
Salvadori M; Bertoni E
G Ital Nefrol; 2010; 27 Suppl 50():S10-8. PubMed ID: 20922691
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
4. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
[TBL] [Abstract][Full Text] [Related]
6. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
8. The role of mTOR in the management of solid tumors: an overview.
Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
[TBL] [Abstract][Full Text] [Related]
9. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
11. Defining the role of mTOR in cancer.
Guertin DA; Sabatini DM
Cancer Cell; 2007 Jul; 12(1):9-22. PubMed ID: 17613433
[TBL] [Abstract][Full Text] [Related]
12. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
[TBL] [Abstract][Full Text] [Related]
13. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
14. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
15. mTOR: a placental growth signaling sensor.
Wen HY; Abbasi S; Kellems RE; Xia Y
Placenta; 2005 Apr; 26 Suppl A():S63-9. PubMed ID: 15837070
[TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
Drakos E; Rassidakis GZ; Medeiros LJ
Expert Rev Mol Med; 2008 Feb; 10():e4. PubMed ID: 18241520
[TBL] [Abstract][Full Text] [Related]
18. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
[TBL] [Abstract][Full Text] [Related]
19. [Topics in mTOR pathway and its inhibitors].
Dreyer C; Sablin MP; Faivre S; Raymond E
Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
[TBL] [Abstract][Full Text] [Related]
20. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]